Xenon Pharmaceuticals Inc

NASDAQ:XENEUnited States

Nov 12, 2024

Show headlines and story abstract

• Xenon Pharmaceuticals Q3 Net Loss Widens, from 4:19PM ET on Tuesday Nov 12, 2024 by MT Newswires

  4:19PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: XENE
  04:19 PM EST, 11/12/2024 (MT Newswires) -- Xenon Pharmaceuticals (XENE) reported a Q3 net loss late Tuesday of $0.81 per diluted share, widening from the loss of $0.73 a year earlier. Analysts polled by Capital IQ expected a loss of $0.81. No revenu...

• *DJ Xenon Pharmaceuticals 3Q Loss/Shr 81c >XENE, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones

  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: XENE
  
  Xenon's Phase 3 epilepsy program includes three ongoing Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the DBP of azetukalner compared to placebo. Upon completion of the double-blind period in the Phase 3 epilepsy studies, eligible patients may enter an OLE study for up to three years.